Literature DB >> 8417333

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

C A Finlay1.   

Abstract

Expression of a p53-associated protein, Mdm-2 (murine double minute-2), can inhibit p53-mediated transactivation. In this study, overexpression of the Mdm-2 protein was found to result in the immortalization of primary rat embryo fibroblasts (REFs) and, in conjunction with an activated ras gene, in the transformation of REFs. The effect of wild-type p53 on the transforming properties of mdm-2 was determined by transfecting REFs with ras, mdm-2, and normal p53 genes. Transfection with ras plus mdm-2 plus wild-type p53 resulted in a 50% reduction in the number of transformed foci (relative to the level for ras plus mdm-2); however, more than half (9 of 17) of the cell lines derived from these foci expressed low levels of a murine p53 protein with the characteristics of a wild-type p53. These results are in contrast to previous studies which demonstrated that even minimal levels of wild-type p53 are not tolerated in cells transformed by ras plus myc, E1A, or mutant p53. The mdm-2 oncogene can overcome the previously demonstrated growth-suppressive properties of p53.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417333      PMCID: PMC358909          DOI: 10.1128/mcb.13.1.301-306.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding.

Authors:  D Michael-Michalovitz; F Yehiely; E Gottlieb; M Oren
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.

Authors:  J Milner; E A Medcalf; A C Cook
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

4.  Different tumor-derived p53 mutants exhibit distinct biological activities.

Authors:  O Halevy; D Michalovitz; M Oren
Journal:  Science       Date:  1990-10-05       Impact factor: 47.728

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.

Authors:  T Crook; J A Tidy; K H Vousden
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

8.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Authors:  P W Hinds; C A Finlay; R S Quartin; S J Baker; E R Fearon; B Vogelstein; A J Levine
Journal:  Cell Growth Differ       Date:  1990-12

9.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Authors:  S S Fakharzadeh; S P Trusko; D L George
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

10.  Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription.

Authors:  M S Lechner; D H Mack; A B Finicle; T Crook; K H Vousden; L A Laimins
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

View more
  92 in total

1.  MdmX protects p53 from Mdm2-mediated degradation.

Authors:  M W Jackson; S J Berberich
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.

Authors:  L McKendrick; D Milne; D Meek
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

Review 3.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

4.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

6.  Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts.

Authors:  Tina M Beachy; Sara L Cole; Jane F Cavender; Mary J Tevethia
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

8.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

9.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

10.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.